Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection
Prabhakaran Kumar, Manikannan Mathayan, Sandra P Smieszek, Bartlomiej P Przychodzen, Vuk Koprivica, Gunther Birznieks, Mihael H Polymeropoulos, Bellur S Prabhakar, Prabhakaran Kumar, Manikannan Mathayan, Sandra P Smieszek, Bartlomiej P Przychodzen, Vuk Koprivica, Gunther Birznieks, Mihael H Polymeropoulos, Bellur S Prabhakar
Abstract
Recurrent waves of COVID19 remain a major global health concern. Repurposing either FDA-approved or clinically advanced drug candidates can save time and effort required for validating the safety profile and FDA approval. However, the selection of appropriate screening approaches is key to identifying novel candidate drugs with a higher probability of clinical success. Here, we report a rapid, stratified two-step screening approach using pseudovirus entry inhibition assay followed by an infectious prototypic SARS CoV2 cytotoxic effect inhibition assay in multiple cell lines. Using this approach, we screened a library of FDA-approved and clinical-stage drugs and identified four compounds, apilimod, berbamine, cepharanthine and (S)-crizotinib which potently inhibited SARS CoV2-induced cell death. Importantly, these drugs exerted similar inhibitory effect on the delta and omicron variants although they replicated less efficiently than the prototypic strain. Apilimod is currently under clinical trial (NCT04446377) for COVID19 supporting the validity and robustness of our screening approach.
Keywords: Anti-viral drug repurposing; Delta; Omicron; SARS CoV2.
Published by Elsevier Inc.
Figures
References
- Consortium W.S.T. Repurposed antiviral drugs for Covid-19-interim WHO solidarity trial results. N. Engl. J. Med. 2021;384:497–511.
- Dai X., Guo G., Zou P., Cui R., Chen W., Chen X., Yin C., He W., Vinothkumar R., Yang F., Zhang X., Liang G. (S)-crizotinib induces apoptosis in human non-small cell lung cancer cells by activating ROS independent of MTH1. J. Exp. Clin. Cancer Res. 2017;36:120.
- Dejnirattisai W., Huo J., Zhou D., Zahradnik J., Supasa P., Liu C., Duyvesteyn H.M.E., Ginn H.M., Mentzer A.J., Tuekprakhon A., Nutalai R., Wang B., Dijokaite A., Khan S., Avinoam O., Bahar M., Skelly D., Adele S., Johnson S.A., Amini A., Ritter T., Mason C., Dold C., Pan D., Assadi S., Bellass A., Omo-Dare N., Koeckerling D., Flaxman A., Jenkin D., Aley P.K., Voysey M., Costa Clemens S.A., Naveca F.G., Nascimento V., Nascimento F., Fernandes da Costa C., Resende P.C., Pauvolid-Correa A., Siqueira M.M., Baillie V., Serafin N., Ditse Z., Silva K.D., Madhi S., Nunes M.C., Malik T., Openshaw P.J., Baillie J.K., Semple M.G., Townsend A.R., Huang K.A., Tan T.K., Carroll M.W., Klenerman P., Barnes E., Dunachie S.J., Constantinides B., Webster H., Crook D., Pollard A.J., Lambe T., consortium O., consortium I.C., Paterson N.G., Williams M.A., Hall D.R., Fry E.E., Mongkolsapaya J., Ren J., Schreiber G., Stuart D.I., Screaton G.R. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv. 2021
- Edara V.V., Pinsky B.A., Suthar M.S., Lai L.L., Davis-Gardner M.E., Floyd K., Flowers M.W., Wrammert J., Hussaini L., Ciric C.R., Bechnak S., Stephens K., Graham B.S., Mokhtari E.B., Mudvari P., Boritz E., Creanga A., Pegu A., Derrien-Colemyn A., Henry A.R., Gagne M., Douek D.C., Sahoo M.K., Sibai M., Solis D., Webby R.J., Jeevan T., Fabrizio T.P. Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N. Engl. J. Med. 2021;385:664–666.
- Elshabrawy H.A., Fan J.L., Haddad C.S., Ratia K., Broder C.C., Caffrey M., Prabhakar B.S. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay. J. Virol. 2014;88:4353–4365.
- Gunst J.D., Staerke N.B., Pahus M.H., Kristensen L.H., Bodilsen J., Lohse N., Dalgaard L.S., Bronnum D., Frobert O., Honge B., Johansen I.S., Monrad I., Erikstrup C., Rosendal R., Vilstrup E., Mariager T., Bove D.G., Offersen R., Shakar S., Cajander S., Jorgensen N.P., Sritharan S.S., Breining P., Jespersen S., Mortensen K.L., Jensen M.L., Kolte L., Frattari G.S., Larsen C.S., Storgaard M., Nielsen L.P., Tolstrup M., Saedder E.A., Ostergaard L.J., Ngo H.T.T., Jensen M.H., Hojen J.F., Kjolby M., Sogaard O.S. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. Eclinicalmedicine. 2021;35
- Ho T.C., Wang Y.H., Chen Y.L., Tsai W.C., Lee C.H., Chuang K.P., Chen Y.A., Yuan C.H., Ho S.Y., Yang M.H., Tyan Y.C. Chloroquine and hydroxychloroquine: efficacy in the treatment of the COVID-19. Pathogens. 2021;10
- Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Muller M.A., Drosten C., Pohlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271. +
- Hoffmann M., Mosbauer K., Hofmann-Winkler H., Kaul A., Kleine-Weber H., Kruger N., Gassen N.C., Muller M.A., Drosten C., Pohlmann S. Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2. Nature. 2020;585:588–590.
- Hsing L.C., Rudensky A.Y. The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol. Rev. 2005;207:229–241.
- Huang L., Yuen T.T., Ye Z., Liu S., Zhang G., Chu H., Yue J. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2. Signal Transduct. Targeted Ther. 2021;6:168.
- Huber K.V., Salah E., Radic B., Gridling M., Elkins J.M., Stukalov A., Jemth A.S., Gokturk C., Sanjiv K., Stromberg K., Pham T., Berglund U.W., Colinge J., Bennett K.L., Loizou J.I., Helleday T., Knapp S., Superti-Furga G. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014;508:222–227.
- Hui K.P.Y., Ho J.C.W., Cheung M.C., Ng K.C., Ching R.H.H., Lai K.L., Kam T.T., Gu H., Sit K.Y., Hsin M.K.Y., Au T.W.K., Poon L.L.M., Peiris M., Nicholls J.M., Chan M.C.W. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715–720.
- Kang Y.L., Chou Y.Y., Rothlauf P.W., Liu Z., Soh T.K., Cureton D., Case J.B., Chen R.E., Diamond M.S., Whelan S.P.J., Kirchhausen T. Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2. Proc. Natl. Acad. Sci. U. S. A. 2020;117:20803–20813.
- Kaye M. SARS-associated coronavirus replication in cell lines. Emerg. Infect. Dis. 2006;12:128–133.
- Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J., Group S.W. A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 2003;348:1953–1966.
- Liu J., Cao R.Y., Xu M.Y., Wang X., Zhang H.Y., Hu H.R., Li Y.F., Hu Z.H., Zhong W., Wang M.L. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6
- Marconi V.C., Ramanan A.V., de Bono S., Kartman C.E., Krishnan V., Liao R., Piruzeli M.L.B., Goldman J.D., Alatorre-Alexander J., Pellegrini R.D., Estrada V., Som M., Cardoso A., Chakladar S., Crowe B., Reis P., Zhang X., Adams D.H., Ely E.W., Grp C.-B.S. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER) : a randomised, double-blind, parallel-group, placebo- controlled phase 3 trial. Lancet Respir. Med. 2021;9:1407–1418.
- Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., Zepeda S.K., Papa G., Kemp S.A., Ikeda T., Toyoda M., Tan T.S., Kuramochi J., Mitsunaga S., Ueno T., Shirakawa K., Takaori-Kondo A., Brevini T., Mallery D.L., Charles O.J., Collaboration C.-N.B.C.-., Genotype to Phenotype Japan, C. Ecuador C.C., Bowen J.E., Joshi A., Walls A.C., Jackson L., Martin D., Smith K.G.C., Bradley J., Briggs J.A.G., Choi J., Madissoon E., Meyer K.B., Mlcochova P., Ceron-Gutierrez L., Doffinger R., Teichmann S.A., Fisher A.J., Pizzuto M.S., de Marco A., Corti D., Hosmillo M., Lee J.H., James L.C., Thukral L., Veesler D., Sigal A., Sampaziotis F., Goodfellow I.G., Matheson N.J., Sato K., Gupta R.K. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714.
- Muller C., Hardt M., Schwudke D., Neuman B.W., Pleschka S., Ziebuhr J. Inhibition of Cytosolic phospholipase A2alpha impairs an early step of coronavirus replication in cell culture. J. Virol. 2018;92
- Ogando N.S., Dalebout T.J., Zevenhoven-Dobbe J.C., Limpens R., van der Meer Y., Caly L., Druce J., de Vries J.J.C., Kikkert M., Barcena M., Sidorov I., Snijder E.J. SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology. J. Gen. Virol. 2020;101:925–940.
- Ohashi H., Watashi K., Saso W., Shionoya K., Iwanami S., Hirokawa T., Shirai T., Kanaya S., Ito Y., Kim K.S., Nomura T., Suzuki T., Nishioka K., Ando S., Ejima K., Koizumi Y., Tanaka T., Aoki S., Kuramochi K., Suzuki T., Hashiguchi T., Maenaka K., Matano T., Muramatsu M., Saijo M., Aihara K., Iwami S., Takeda M., McKeating J.A., Wakita T. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021;24:102367.
- Pia L., Rowland-Jones S. Omicron entry route. Nat. Rev. Immunol. 2022;22:145. 145.
- Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., Prot M., Gallais F., Gantner P., Velay A., Le Guen J., Kassis-Chikhani N., Edriss D., Belec L., Seve A., Courtellemont L., Pere H., Hocqueloux L., Fafi-Kremer S., Prazuck T., Mouquet H., Bruel T., Simon-Loriere E., Rey F.A., Schwartz O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280.
- Rajpoot S., Alagumuthu M., Baig M.S. Dual targeting of 3CL(pro) and PL(pro) of SARS-CoV-2: a novel structure-based design approach to treat COVID-19. Curr. Res. Struct. Biol. 2021;3:9–18.
- Riva L., Yuan S., Yin X., Martin-Sancho L., Matsunaga N., Pache L., Burgstaller-Muehlbacher S., De Jesus P.D., Teriete P., Hull M.V., Chang M.W., Chan J.F., Cao J., Poon V.K., Herbert K.M., Cheng K., Nguyen T.H., Rubanov A., Pu Y., Nguyen C., Choi A., Rathnasinghe R., Schotsaert M., Miorin L., Dejosez M., Zwaka T.P., Sit K.Y., Martinez-Sobrido L., Liu W.C., White K.M., Chapman M.E., Lendy E.K., Glynne R.J., Albrecht R., Ruppin E., Mesecar A.D., Johnson J.R., Benner C., Sun R., Schultz P.G., Su A.I., Garcia-Sastre A., Chatterjee A.K., Yuen K.Y., Chanda S.K. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature. 2020;586:113–119.
- Rutherford A.C., Traer C., Wassmer T., Pattni K., Bujny M.V., Carlton J.G., Stenmark H., Cullen P.J. The mammalian phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. J. Cell Sci. 2006;119:3944–3957.
- Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. P Natl Acad. Sci. USA. 2005;102:11876–11881.
- Syed A.M., Ciling A., Khalid M.M., Sreekumar B., Chen P.Y., Kumar G.R., Silva I., Milbes B., Kojima N., Hess V., Shacreaw M., Lopez L., Brobeck M., Turner F., Spraggon L., Taha T.Y., Tabata T., Chen I.P., Ott M., Doudna J.A. medRxiv; 2022. Omicron Mutations Enhance Infectivity and Reduce Antibody Neutralization of SARS-CoV-2 Virus-like Particles.
- Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M., Iwatsuki-Horimoto K., Chiba S., Halfmann P., Nagai H., Saito M., Adachi E., Sullivan D., Pekosz A., Watanabe S., Maeda K., Imai M., Yotsuyanagi H., Mitsuya H., Ohmagari N., Takeda M., Hasegawa H., Kawaoka Y. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N. Engl. J. Med. 2022
- Tummino T.A., Rezelj V.V., Fischer B., Fischer A., O'Meara M.J., Monel B., Vallet T., White K.M., Zhang Z., Alon A., Schadt H., O'Donnell H.R., Lyu J., Rosales R., McGovern B.L., Rathnasinghe R., Jangra S., Schotsaert M., Galarneau J.R., Krogan N.J., Urban L., Shokat K.M., Kruse A.C., Garcia-Sastre A., Schwartz O., Moretti F., Vignuzzi M., Pognan F., Shoichet B.K. Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. Science. 2021;373:541–547.
- V'Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155–170.
- Wang M.L., Cao R.Y., Zhang L.K., Yang X.L., Liu J., Xu M.Y., Shi Z.L., Hu Z.H., Zhong W., Xiao G.F. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271.
- Yan K., Rawle D.J., Le T.T., Suhrbier A. Simple rapid in vitro screening method for SARS-CoV-2 anti-virals that identifies potential cytomorbidity-associated false positives. Virol. J. 2021;18:123.
- Zhang Z.R., Zhang Y.N., Zhang H.Q., Zhang Q.Y., Li N., Li Q., Deng C.L., Zhang B., Li X.D., Ye H.Q. Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusion. PLoS Neglected Trop. Dis. 2022;16
- Zhao H.J., Lu L., Peng Z., Chen L.L., Meng X.J., Zhang C.Y., Ip J.D., Chan W.M., Chu A.W.H., Chan W.H., Jin D.Y., Chen H.L., Yuen W.Y., To K.K.W. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microb. Infect. 2022;11:277–283.
- Zhao M.M., Yang W.L., Yang F.Y., Zhang L., Huang W.J., Hou W., Fan C.F., Jin R.H., Feng Y.M., Wang Y.C., Yang J.K. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development. Signal Transduct Tar. 2021;6
- Zhu Y.K., Feng F., Hu G.W., Wang Y.Y., Yu Y., Zhu Y.F., Xu W., Cai X., Sun Z.P., Han W.D., Ye R., Qu D., Ding Q., Huang X.X., Chen H.J., Xu W., Xie Y.H., Cai Q.L., Yuan Z.H., Zhang R. A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. Nat. Commun. 2021;12
Source: PubMed